<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dabrafenib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dabrafenib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dabrafenib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="89749" href="/d/html/89749.html" rel="external">see "Dabrafenib: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="139458" href="/d/html/139458.html" rel="external">see "Dabrafenib: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F20617042"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tafinlar</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871619"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Tafinlar</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F20498983"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, BRAF Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F20608805"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Confirm BRAF V600 mutation status (in tumor specimens) prior to dabrafenib treatment initiation. Secondary prophylaxis with antipyretics may be required when resuming dabrafenib following a severe febrile drug reaction.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c342c9c8-af4e-4e86-966a-b9892e44238d">Melanoma, adjuvant treatment, with <i>BRAF</i> V600E or <i>BRAF</i> V600K mutation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, adjuvant treatment, with <i>BRAF</i> V600E or <i>BRAF</i> V600K mutation:</b>
<b>Oral:</b> 150 mg twice daily, approximately every 12 hours (in combination with trametinib); continue for up to 1 year in the absence of disease recurrence or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32877599','lexi-content-ref-28891408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32877599','lexi-content-ref-28891408'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dba8b3bc-a304-4bc0-a291-dd4fd8968c0c">Melanoma, metastatic or unresectable, with <i>BRAF</i> V600E or <i>BRAF</i> V600K mutation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, metastatic or unresectable, with <i>BRAF</i> V600E or <i>BRAF</i> V600K mutation</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Melanoma, metastatic or unresectable, with <i>BRAF</i> V600E mutation (single-agent therapy):</b>
<b>Oral:</b> 150 mg twice daily, approximately every 12 hours (single-agent therapy); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22735384','lexi-content-ref-23051966']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22735384','lexi-content-ref-23051966'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Melanoma, metastatic or unresectable, with <i>BRAF</i> V600E or <i>BRAF</i> V600K mutation (combination therapy):</b>
<b>Oral:</b> 150 mg twice daily, approximately every 12 hours (in combination with trametinib); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26037941','lexi-content-ref-25399551']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26037941','lexi-content-ref-25399551'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16541d7c-b248-4204-a4dc-9f33ab767f38">Non–small cell lung cancer, metastatic, with <i>BRAF V600E</i> mutation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic, with <i>BRAF</i> V600E mutation: Oral:</b> 150 mg twice daily, approximately every 12 hours (in combination with trametinib); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27283860','lexi-content-ref-34455067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27283860','lexi-content-ref-34455067'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="053903e2-ce35-4937-a1fc-4f4fddebef29">Solid tumors, unresectable or metastatic, with <i>BRAF</i> V600E mutation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors, unresectable or metastatic, with BRAF V600E mutation: Oral:</b> 150 mg twice daily, approximately every 12 hours (in combination with trametinib); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32758030','lexi-content-ref-32818466','lexi-content-ref-34838156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32758030','lexi-content-ref-32818466','lexi-content-ref-34838156'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ca19d94f-f4d4-4459-844f-f5f10b27fa62">Thyroid cancer, anaplastic, locally advanced or metastatic, with <i>BRAF</i> V600E mutation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, anaplastic, locally advanced or metastatic, with <i>BRAF</i> V600E mutation: Oral:</b> 150 mg twice daily, approximately every 12 hours (in combination with trametinib); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29072975','lexi-content-ref-35026411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29072975','lexi-content-ref-35026411'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Missed or vomited doses:</i> A missed dose may be administered up to 6 hours prior to the next dose; do not administer if &lt;6 hours until the next dose (do not make up for the missed dose). If a dose is vomited, do not administer an additional dose; administer the next dose at its scheduled time.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990740"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; however, pharmacokinetic differences with eGFR ≥15 mL/minute/1.73 m<sup>2 </sup>are not considered clinically relevant.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988119"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (bilirubin ≤ ULN and AST &gt; ULN <b>or</b> bilirubin &gt;1 to 1.5 times ULN and any AST): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate (bilirubin &gt;1.5 to 3 times ULN and any AST) to severe (bilirubin &gt;3 to 10 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (an appropriate dose has not been established); however, hepatic metabolism and biliary excretion are the primary elimination routes for dabrafenib, and exposure may be increased in patients with moderate to severe impairment.</p></div>
<div class="block dot drugH1Div" id="F20608809"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Dabrafenib Capsule Dosage Reduction Levels</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Usual (initial) dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg twice daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">First dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg twice daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg twice daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Third dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg twice daily</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">If unable to tolerate 50 mg twice daily, permanently discontinue dabrafenib.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> If using combination therapy, refer to Trametinib monograph for recommended trametinib dose modification.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Dabrafenib Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reactions</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Description/severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dabrafenib dosage modification</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> LVEF = left ventricular ejection fraction.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Cardiomyopathy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;20% absolute decrease in LVEF<sup>a</sup> from baseline that is below institutional LLN</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib until LVEF<sup>a</sup> improves to at least the institutional LLN and absolute decrease to ≤10% (compared to baseline), then resume at the same dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Symptomatic heart failure</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib until LVEF<sup>a</sup> improves to at least the institutional LLN and absolute decrease to ≤10% (compared to baseline), then resume at the same dose.</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Dermatologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Intolerable grade 2 adverse reaction or grade 3 or 4 adverse reaction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib for up to 3 weeks. If improved, resume dabrafenib at a lower dose. If not improved, permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">New primary cutaneous malignancy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dabrafenib dosage modification is necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe cutaneous adverse reactions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Febrile reactions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fever of 38°C to 40°C (100.4°F to 104°F), or first symptoms in case of recurrence</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib until fever resolves and then resume at the same or lower dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fever &gt;40°C (104°F) and/or fever complicated by rigors, hypotension, dehydration, or renal failure</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib until febrile reaction resolves for at least 24 hours, then resume at a lower dose or permanently discontinue.</p>
<p style="text-indent:0em;text-align:left;">Administer antipyretics (as secondary prophylaxis) upon dabrafenib resumption if patient had a prior episode of severe febrile reaction or fever associated with complications. Administer corticosteroids (eg, prednisone 10 mg daily or equivalent) for at least 5 days for second or subsequent pyrexia if temperature does not return to baseline within 3 days of onset of fever, or for fever associated with complications (eg, dehydration, renal failure, hypotension, severe chills/rigors with no evidence of active infection).</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Hemophagocytic lymphohistiocytosis</p></td>
<td align="left">
<p style="text-indent:0em;">Suspected</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt dabrafenib treatment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Confirmed</p></td>
<td align="left">
<p style="text-indent:0em;">Discontinue dabrafenib and manage as appropriate.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Hemorrhage</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Intolerable grade 2 or grade 3 hemorrhage</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib therapy. If hemorrhage improves to ≤ grade 1, resume dabrafenib at a lower dose. If grade 3 hemorrhage does not improve following therapy interruption, permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 hemorrhage</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hyperglycemia</p></td>
<td align="left"></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hyperglycemia may require initiation or optimization of insulin or oral hypoglycemic agent therapy (as clinically indicated).</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Ocular toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Retinal pigment epithelial detachment</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dabrafenib dosage modification is necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Retinal vein occlusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dabrafenib dosage modification is necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Uveitis, including iritis and iridocyclitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Manage symptomatically with local ophthalmic therapy (steroid and mydriatic drops were used in clinical trials) while continuing dabrafenib. For mild or moderate uveitis that does not respond to local ocular therapy (or for severe uveitis), interrupt dabrafenib for up to 6 weeks; if improved to ≤ grade 1, resume dabrafenib at the same or lower dose. If not improved, or for persistent grade 2 or higher uveitis of &gt;6 weeks duration, permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pulmonary toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interstitial lung disease or pneumonitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dabrafenib dosage modification is necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Venous thromboembolism</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Uncomplicated</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dabrafenib dosage modification is necessary.</p></td></tr>
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;text-align:left;">Other toxicities</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Intolerable grade 2 or any grade 3 adverse reaction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib therapy until resolution to ≤ grade 1; then resume dabrafenib at a lower dose. If adverse reaction does not improve, permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 adverse reaction (first occurrence)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib until resolution to ≤ grade 1; then resume dabrafenib at lower dose or permanently discontinue.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 adverse reaction (recurrent after dosage reduction)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">New primary noncutaneous malignancy (RAS mutation-positive)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue dabrafenib.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F20608806"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F57137231"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="139458" href="/d/html/139458.html" rel="external">see "Dabrafenib: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Dabrafenib is available as tablets for oral suspension and capsules; weight-band dosing is product specific in patients &lt;18 years of age due to product strengths.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1b4c0473-1817-4b8c-9c79-296fb24a87f0">Glioma, low-grade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glioma, low-grade (LGG) (with <i>BRAF</i> V600E mutation): Note:</b> Use in combination with trametinib and continue therapy until disease progression or unacceptable toxicity. Twice-daily doses should be separated by 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing</i>: Limited data available: <b>Note:</b> In clinical trial experience, both dosage forms, tablets for oral suspension and capsules, were used based on patient's ability to swallow capsules (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36375115']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36375115'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 1 to &lt;12 years: Oral: 2.63 mg/kg/dose every 12 hours; maximum dose: 150 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36375115','lexi-content-ref-31811016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36375115','lexi-content-ref-31811016'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents &lt;18 years: Oral: 2.25 mg/kg/dose every 12 hours; maximum dose: 150 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36375115','lexi-content-ref-31811016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36375115','lexi-content-ref-31811016'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-band dosing:</i> Children ≥1 year and Adolescents: Oral:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:left;">
<b>Dabrafenib Weight-Band Dosing for Low-Grade Glioma in Children ≥1 Year and Adolescents</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Patient Weight (kg)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Tablets for Oral Suspension</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Capsules</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">8 to &lt;10 kg</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">10 to &lt;14 kg</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">14 to &lt;18 kg</p></td>
<td align="left">
<p style="text-indent:0em;">40 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">18 to &lt;22 kg</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">22 to &lt;26 kg</p></td>
<td align="left">
<p style="text-indent:0em;">60 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">26 to &lt;30 kg</p></td>
<td align="left">
<p style="text-indent:0em;">70 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">30 to &lt;34 kg</p></td>
<td align="left">
<p style="text-indent:0em;">80 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">34 to &lt;38 kg</p></td>
<td align="left">
<p style="text-indent:0em;">90 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">38 to &lt;42 kg</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">42 to &lt;46 kg</p></td>
<td align="left">
<p style="text-indent:0em;">110 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">46 to &lt;51 kg</p></td>
<td align="left">
<p style="text-indent:0em;">130 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥51 kg</p></td>
<td align="left">
<p style="text-indent:0em;">150 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">150 mg twice daily</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="154d4fa3-a170-41f4-a413-b7f7e8053a1e">Solid tumors, unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors, unresectable or metastatic (<i>BRAF</i> V600E mutation):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients who have progressed following prior treatment and have no satisfactory alternative treatment options. Approval for solid tumors is from an accelerated process and subject to change as data evolves. Use in combination with trametinib and continue therapy until disease progression or unacceptable toxicity. Twice-daily doses should be separated by 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing: </i>Limited data available: <b>Note:</b> In the trial, both dosage forms, tablets for oral suspension and capsules, were used based on patient's ability to swallow capsules (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31506385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31506385'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 1 to &lt;12 years: Oral: 2.63 mg/kg/dose every 12 hours; maximum dose: 150 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31506385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31506385'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents &lt;18 years: Oral: 2.25 mg/kg/dose every 12 hours; maximum dose: 150 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31506385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31506385'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-band dosing:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥1 year and Adolescents: Oral: <i></i></p>
<table border="1" frame="border" rules="all" style="margin-left:10em;">
<caption style="text-align:left;">
<b>Dabrafenib Weight-Band Dosing for Solid Tumors (Unresectable or Metastatic) in Children ≥1 Year and Adolescents</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Patient Weight (kg)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Tablets for Oral Suspension</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Capsules</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">8 to &lt;10 kg</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">10 to &lt;14 kg</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">14 to &lt;18 kg</p></td>
<td align="left">
<p style="text-indent:0em;">40 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">18 to &lt;22 kg</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">22 to &lt;26 kg</p></td>
<td align="left">
<p style="text-indent:0em;">60 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">26 to &lt;30 kg</p></td>
<td align="left">
<p style="text-indent:0em;">70 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">30 to &lt;34 kg</p></td>
<td align="left">
<p style="text-indent:0em;">80 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">34 to &lt;38 kg</p></td>
<td align="left">
<p style="text-indent:0em;">90 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">38 to &lt;42 kg</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">42 to &lt;46 kg</p></td>
<td align="left">
<p style="text-indent:0em;">110 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">46 to &lt;51 kg</p></td>
<td align="left">
<p style="text-indent:0em;">130 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥51 kg</p></td>
<td align="left">
<p style="text-indent:0em;">150 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">150 mg twice daily</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Dose reduction levels:</i> Note:</b> In patients &lt;18 years of age, dosage adjustments are dosage form specific (tablets for oral suspension or capsules).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tablets for oral suspension: </i></p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:left;">
<b>Dabrafenib Tablets for Oral Suspension Dosage Level Reductions in Ages 1 to &lt;18 Years</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Patient Weight (Usual Dose)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>First Dose Reduction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Second Dose Reduction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Third Dose Reduction</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">8 to &lt;10 kg</p>
<p style="text-indent:0em;margin-top:2em;">(20 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">10 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">10 to &lt;14 kg</p>
<p style="text-indent:0em;margin-top:2em;">(30 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">10 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">14 to &lt;18 kg</p>
<p style="text-indent:0em;margin-top:2em;">(40 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">10 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">18 to &lt;22 kg</p>
<p style="text-indent:0em;margin-top:2em;">(50 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">10 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">22 to &lt;26 kg</p>
<p style="text-indent:0em;margin-top:2em;">(60 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">40 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">26 to &lt;30 kg</p>
<p style="text-indent:0em;margin-top:2em;">(70 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">40 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">30 to &lt;34 kg</p>
<p style="text-indent:0em;margin-top:2em;">(80 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">40 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">34 to &lt;38 kg</p>
<p style="text-indent:0em;margin-top:2em;">(90 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">60 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">38 to &lt;42 kg</p>
<p style="text-indent:0em;margin-top:2em;">(100 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">70 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">30 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">42 to &lt;46 kg</p>
<p style="text-indent:0em;margin-top:2em;">(110 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">70 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">60 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">40 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">46 to &lt;51 kg</p>
<p style="text-indent:0em;margin-top:2em;">(130 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">90 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">70 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">40 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥51 kg</p>
<p style="text-indent:0em;margin-top:2em;">(150 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">80 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>Capsules:</i></p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:left;">
<b>Dabrafenib Capsule Dosage Level Reductions in Ages 1 to &lt;18 Years Weighing ≥26 kg</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Patient Weight (Usual Dose)</p></th>
<th align="left">
<p style="text-indent:0em;">First Dose Reduction</p></th>
<th align="left">
<p style="text-indent:0em;">Second Dose Reduction</p></th>
<th align="left">
<p style="text-indent:0em;">Third Dose Reduction</p></th>
<th align="left">
<p style="text-indent:0em;">Subsequent Modifications</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">26 to &lt;38 kg</p>
<p style="text-indent:0em;margin-top:2em;">(75 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td>
<td align="left" colspan="3">
<p style="text-indent:0em;">Permanently discontinue if unable to tolerate 50 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">38 to &lt;51 kg</p>
<p style="text-indent:0em;margin-top:2em;">(100 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">Permanently discontinue if unable to tolerate 50 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥51 kg</p>
<p style="text-indent:0em;margin-top:2em;">(150 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue if unable to tolerate 50 mg twice daily</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:left;">
<b>Dabrafenib Capsule Dosage Level Reductions in Ages ≥18 Years</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Usual Dose</p></th>
<th align="left">
<p style="text-indent:0em;">First Dose Reduction</p></th>
<th align="left">
<p style="text-indent:0em;">Second Dose Reduction</p></th>
<th align="left">
<p style="text-indent:0em;">Third Dose Reduction</p></th>
<th align="left">
<p style="text-indent:0em;">Subsequent Modifications</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">150 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue if unable to tolerate 50 mg twice daily</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Dosage adjustments:</b></i>
<b>Note:</b> If using combination therapy with trametinib, other adverse reactions related to trametinib may occur; refer to Trametinib monograph for detailed information.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:left;">
<b>Dabrafenib Dosage Modifications for Adverse Reactions in Pediatric Patients ≥1 Year of Age</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse Reactions</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Description/Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dabrafenib Dosage Modification</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> LVEF = left ventricular ejection fraction.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Cardiomyopathy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;20% absolute decrease in LVEF<sup>a</sup> from baseline that is below institutional LLN</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib until LVEF<sup>a</sup> improves to at least the institutional LLN and absolute decrease to ≤10% (compared to baseline), then resume at the same dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Symptomatic heart failure</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib until LVEF<sup>a</sup> improves to at least the institutional LLN and absolute decrease to ≤10% (compared to baseline), then resume at the same dose.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Dermatologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Intolerable grade 2 adverse reaction or grade 3 or 4 adverse reaction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib for up to 3 weeks. If improved, resume dabrafenib at a lower dose. If not improved, permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe cutaneous adverse reactions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Febrile reactions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fever of 38°C to 40°C (100.4°F to 104°F), or first symptoms in case of recurrence</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib until fever resolves and then resume at the same or lower dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fever &gt;40°C (104°F) and/or fever complicated by rigors, hypotension, dehydration, or kidney failure</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib until febrile reaction resolves for at least 24 hours, then resume at a lower dose or permanently discontinue.</p>
<p style="text-indent:0em;text-align:left;">Administer antipyretics (as secondary prophylaxis) upon dabrafenib resumption if patient had a prior episode of severe febrile reaction or fever associated with complications. Administer corticosteroids (eg equivalent of prednisone 10 mg daily in adults) for ≥5 days for a second or subsequent pyrexia if temperature does not return to baseline within 3 days of onset of fever, or for fever associated with complications (eg, dehydration, kidney failure, hypotension, severe chills/rigors with no evidence of active infection).</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Hemorrhage</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Intolerable grade 2 or any grade 3 hemorrhage</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib therapy. If hemorrhage improves to grade 0 or 1, resume dabrafenib at a lower dose. If grade 3 does not improve, discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4 first occurrence</p></td>
<td align="left">
<p style="text-indent:0em;">Discontinue or interrupt dabrafenib therapy until improves to grade 0 or 1, then resume at lower dose. If no improvement, permanently discontinue.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 recurrent</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hyperglycemia</p></td>
<td align="left"></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hyperglycemia may require initiation or optimization of insulin or oral hypoglycemic agent therapy (as clinically indicated).</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">New primary malignancies</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">New primary cutaneous malignancy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dabrafenib dosage modification is necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Noncutaneous RAS mutation-positive malignancies</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Ocular toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Uveitis, including iritis and iridocyclitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Manage symptomatically with local ophthalmic therapy (steroid and mydriatic drops were used in clinical trials) while continuing dabrafenib without dose modification. For iritis, administer ocular treatment. For severe uveitis or mild/moderate uveitis that does not respond to therapy, interrupt dabrafenib and treat as clinically indicated. If improves to grade 0 or 1, resume dabrafenib at the same or lower dose. If not improved, or for persistent grade 2 or higher uveitis of &gt;6 weeks duration, permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Other toxicities</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Intolerable grade 2 or any grade 3 adverse reaction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib therapy until resolution to ≤ grade 1; then resume dabrafenib at a lower dose. If adverse reaction does not improve, permanently discontinue dabrafenib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 adverse reaction (first occurrence)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt dabrafenib until resolution to ≤ grade 1; then resume dabrafenib at a lower dose or permanently discontinue.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 adverse reaction (recurrent after dosage reduction)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue dabrafenib.</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F57137262"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥1 year and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; however, pharmacokinetic differences with eGFR ≥15 mL/minute/1.73 m<sup>2 </sup>are not considered clinically relevant.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F57137263"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥1 year and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (bilirubin ≤ ULN and AST &gt; ULN <b>or</b> bilirubin &gt;1 to 1.5 times ULN and any AST): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate (bilirubin &gt;1.5 to 3 times ULN and any AST) to severe (bilirubin &gt;3 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (an appropriate dose has not been established); however, hepatic metabolism and biliary excretion are the primary elimination routes for dabrafenib and exposure may be increased in patients with moderate to severe impairment.</p></div>
<div class="block adr drugH1Div" id="F20713630"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (22%), hyperkeratosis (37%), palmar-plantar erythrodysesthesia (20%), skin rash (17% to 27%), squamous cell carcinoma of skin (7% to 11%; grade 3: 4%), xeroderma (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (50% to 57%), hyponatremia (8% to 14%), hypophosphatemia (35% to 37%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (10% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Papilloma (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (19% to 25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (17%), headache (30% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (27% to 31%), back pain (12%), myalgia (11% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (12% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (28% to 33%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Basal cell carcinoma of skin (4%), bullous rash (&lt;10%), malignant melanoma (new primary: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Keratoacanthoma (4%), malignant neoplasm (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Uveitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Febrile reaction (serious: 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Fatigue</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hematologic &amp; oncologic: Kaposi sarcoma (Parakh 2016)</p></div>
<div class="block coi drugH1Div" id="F20498986"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<i>Canadian labeling:</i> Hypersensitivity to dabrafenib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F20608787"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiomyopathy: Cardiomyopathy (a decrease in left ventricular ejection fraction [LVEF] ≥10% from baseline and below the institutional lower limit of normal) has occurred when used in combination with trametinib. Cardiomyopathy resolved in most patients receiving dabrafenib in combination with trametinib following dose adjustments, treatment interruption, and/or permanent discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS), may occur when dabrafenib is administered with trametinib and could be life-threatening or fatal. Other serious skin toxicities have also occurred (rare).</p>
<p style="text-indent:-2em;margin-left:4em;">• Febrile reactions: Serious febrile reactions and fever (any severity) complicated by hypotension, rigors or chills, dehydration, or renal failure were observed during dabrafenib single-agent therapy and when used in combination with trametinib. The incidence and severity of fevers were increased when dabrafenib was used in combination with trametinib. Some patients experienced multiple discrete episodes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemophagocytic lymphohistiocytosis: Hemophagocytic lymphohistiocytosis, a life-threatening immune system reaction, has been reported when dabrafenib is used in combination with trametinib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Hemorrhage (including major hemorrhage), defined as symptomatic bleeding in a critical area/organ, may occur with dabrafenib in combination with trametinib. Serious bleeding events (some fatal) included intracranial, cerebral, brainstem, or GI hemorrhage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperglycemia: Hyperglycemia may occur in patients with a history of diabetes while on dabrafenib therapy (either as a single agent or in combination with trametinib).</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Cutaneous squamous cell carcinoma (cuSCC) and keratoacanthoma, basal cell carcinoma (BCC), and new primary melanoma were observed during single-agent dabrafenib therapy. When used in combination with trametinib, cuSCCs (including keratoacanthomas), BCC, and new primary melanoma were reported in small percentages of patients. Noncutaneous malignancies were reported in a small percentage of patients with monotherapy and combination therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular toxicity: Uveitis, including iritis and iridocyclitis, has been reported with dabrafenib single-agent therapy and when used in combination with trametinib. Retinal pigment epithelial detachments (RPED) were seen in clinical trials when used in combination with trametinib (a known complication of trametinib single-agent therapy). Detachments may be bilateral and multifocal, and occurred in the central macular area or elsewhere in the retina.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: QTcF prolongation &gt;60 msec above baseline or to &gt;500 msec was reported (rare), both as a single agent or when used in combination with trametinib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Venous thromboembolism: Venous thromboembolism events such as deep venous thrombosis (DVT) and pulmonary embolism (PE) (some fatal) may occur (rare) when dabrafenib is used in combination with trametinib. Patients should seek immediate medical attention with symptoms of DVT or PE (shortness of breath, chest pain, arm/leg swelling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose-6-phosphate dehydrogenase deficiency: Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at risk for hemolytic anemia when administered dabrafenib.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Exposing wild-type cells to BRAF inhibitors such as dabrafenib may result in paradoxical activation of MAP-kinase signaling and increased cell proliferation. Prior to initiating therapy, confirm BRAF V600E or BRAF V600K mutation status (in tumor specimens) with an approved test. Information on approved tests for detection of BRAF V600 mutations is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2FCompanionDiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IPc%2BkYYsON95PtA1EteUbfjUoJYJ%2BuveJw2PtFUTXMkK&amp;TOPIC_ID=89686" target="_blank">http://www.fda.gov/CompanionDiagnostics</a>. An approved test for BRAF V600E mutation detection in anaplastic thyroid cancer and low-grade glioma is not available.</p></div>
<div class="block foc drugH1Div" id="F20617043"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tafinlar: 50 mg, 75 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Soluble, Oral, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tafinlar: 10 mg</p></div>
<div class="block geq drugH1Div" id="F20608782"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F22686899"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Tafinlar Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $113.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $145.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet,Dispersible</b> (Tafinlar Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $22.61</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871620"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tafinlar: 50 mg, 75 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Soluble, Oral, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tafinlar: 10 mg</p></div>
<div class="block adm drugH1Div" id="F20608811"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Capsules: Administer at least 1 hour before or 2 hours after a meal; doses should be administered ~12 hours apart at approximately the same time(s) each day. Do not open, crush, or break capsules. When administered in combination with trametinib, take the once-daily dose of trametinib at the same time each day with either the morning or evening dose of dabrafenib.</p></div>
<div class="block admp drugH1Div" id="F57137265"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer at least 1 hour before or 2 hours after a meal; doses should be ~12 hours apart. When administered in combination with trametinib, take the once-daily dose of trametinib at the same time each day with either the morning or evening dose of dabrafenib. If vomiting occurs after dose administration, do not repeat or take an additional dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Do not open, crush, or break capsules.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets for oral suspension: Do not swallow whole, chew, or crush tablets for oral suspension. Place tablets for dose in the provided cup. The volume of water to add depends on number of tablets: ~5 mL if dose is 1 to 4 tablets; ~10 mL if dose is 5 to 15 tablets. Stir with the handle of a teaspoon until tablets are fully dissolved; may take ≥3 minutes to fully dissolve; the suspension will be cloudy white once dissolved. Administer dissolved dose immediately via the dosing cup, or pull into an oral dosing syringe to administer by mouth or feeding tube. If not used within 30 minutes of preparation, discard dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> A missed dose may be administered up to 6 hours prior to the next dose; do not administer if &lt;6 hours until the next dose (do not make up for the missed dose).</p></div>
<div class="block hazard drugH1Div" id="F49104466"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block meg drugH1Div" id="F20608780"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F202806s027lbl.pdf%23page%3D46&amp;token=tIQMqW9K%2FJrdm24hDndzJpGAkA9BKbqbDtsLTbYd7BNbUnUi%2BZi%2BxyaYCegvQ1GJ%2F9T07SH8C%2FcOkscozf3MhuFDcfKPO7VS6uUVe1Be88YQRb%2BMXy1QLFXBMhLahYxo&amp;TOPIC_ID=89686" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s027lbl.pdf#page=46</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F20498985"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Glioma, low-grade, with <i>BRAF</i> V600E mutation:</b> Treatment of low-grade glioma with a <i>BRAF</i> V600E mutation (in combination with trametinib) in pediatric patients ≥1 year of age who require systemic therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, adjuvant treatment, with <i>BRAF</i> V600E or <i>BRAF</i> V600K mutation: </b>Adjuvant treatment of melanoma (in combination with trametinib) in patients with <i>BRAF</i> V600E or <i>BRAF</i> V600K mutations (as detected by an approved test), and lymph node(s) involvement, following complete resection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, </b>
<b>metastatic or unresectable, with <i>BRAF</i> V600E or <i>BRAF</i> V600K mutation</b>
<b>: </b>Treatment of unresectable or metastatic melanoma in patients with a <i>BRAF</i> V600E mutation (single agent therapy) or in patients with <i>BRAF</i> V600E or <i>BRAF</i> V600K mutations (in combination with trametinib); confirm <i>BRAF</i> V600E or <i>BRAF</i> V600K mutation status with an approved test prior to treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-small cell lung cancer, metastatic, with <i>BRAF</i> V600E mutation:</b> Treatment of metastatic non-small cell lung cancer (NSCLC) in patients with <i>BRAF</i> V600E mutation as detected by an approved test (in combination with trametinib).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors, unresectable or metastatic, with <i>BRAF</i> V600E mutation: </b>Treatment (in combination with trametinib) of unresectable or metastatic solid tumors with a <i>BRAF</i> V600E mutation in adults and pediatric patients ≥1 year of age who have progressed following prior treatment and have no satisfactory alternative treatment options.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, anaplastic, locally advanced or metastatic, with <i>BRAF</i> V600E mutation:</b> Treatment of locally advanced or metastatic anaplastic thyroid cancer (ATC) (in combination with trametinib) in patients with <i>BRAF</i> V600E mutation and with no satisfactory locoregional treatment options.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Dabrafenib is not indicated for treatment of colorectal cancer because of known intrinsic resistance to BRAF inhibition. Dabrafenib is not indicated for treatment of wild-type BRAF solid tumors.</p></div>
<div class="block mst drugH1Div" id="F20608778"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dabrafenib may be confused with cobimetinib, dacomitinib, dasatinib, duvelisib, encorafenib, trametinib, vemurafenib</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F20797138"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP2C8 (major), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP2C9 (weak), CYP3A4 (moderate)</p></div>
<div class="block dri drugH1Div" id="F20797136"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abiraterone Acetate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Acalabrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALfentanil.  Management: If concomitant use of alfentanil and moderate CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Apremilast. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Artemether and Lumefantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avacopan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: Dabrafenib may enhance the QTc-prolonging effect of Bedaquiline. Dabrafenib may decrease serum concentrations of the active metabolite(s) of Bedaquiline. Dabrafenib may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Belumosudil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brexpiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inducers when possible. If combined, increase the daily dose of brigatinib in 30 mg increments after 7 days of treatment with the current brigatinib dose, up to maximum of twice the dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capivasertib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capmatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: Dabrafenib may enhance the QTc-prolonging effect of Clarithromycin. Dabrafenib may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase serum concentrations of the active metabolite(s) of Dabrafenib. Clarithromycin may increase the serum concentration of Dabrafenib. Dabrafenib may increase the serum concentration of Clarithromycin.  Management: If coadministration is unavoidable, monitor for decreased clarithromycin efficacy, increased dabrafenib adverse effects, and QTc interval prolongation and ventricular arrhythmias when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May enhance the QTc-prolonging effect of Dabrafenib. Clofazimine may increase the serum concentration of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Dabrafenib may enhance the QTc-prolonging effect of CloZAPine. Dabrafenib may decrease the serum concentration of CloZAPine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Additionally, monitor for decreased clozapine concentrations and efficacy.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: Dabrafenib may enhance the QTc-prolonging effect of Crizotinib. Dabrafenib may decrease the serum concentration of Crizotinib. Crizotinib may increase the serum concentration of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Additionally, monitor for decreased crizotinib efficacy and increased dabrafenib adverse effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Moderate): May increase the serum concentration of Dabrafenib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Strong): May increase the serum concentration of Dabrafenib. Management: Consider alternatives to strong CYP2C8 inhibitors in patients being treated with dabrafenib. If such a combination cannot be avoided, monitor closely for evidence of dabrafenib-related adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Dabrafenib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dabrafenib. Management: Consider alternatives to any strong CYP3A4 inhibitor for patients being treated with dabrafenib. If such a combination cannot be avoided, monitor closely for evidence of dabrafenib-related adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daclatasvir.  Management: Increase the daclatasvir dose to 90 mg once daily if used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dapsone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inducers (Moderate) may increase the serum concentration of Dasatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Delavirdine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: Dabrafenib may enhance the QTc-prolonging effect of Disopyramide. Dabrafenib may decrease the serum concentration of Disopyramide.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and reduced disopyramide efficacy. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doravirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Doravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: Dabrafenib may enhance the QTc-prolonging effect of Dronedarone. Dabrafenib may decrease the serum concentration of Dronedarone. Dronedarone may increase the serum concentration of Dabrafenib.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias. Also monitor for decreased dronedarone and increased dabrafenib concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Duvelisib.  Management: Avoid if possible. If used, on day 12 of combination increase duvelisib from 25 mg twice daily to 40 mg twice daily or from 15 mg twice daily to 25 mg twice daily. Resume prior duvelisib dose 14 days after stopping moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Efavirenz. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Eliglustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elvitegravir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: Dabrafenib may enhance the QTc-prolonging effect of Encorafenib. Encorafenib may decrease the serum concentration of Dabrafenib. Dabrafenib may decrease the serum concentration of Encorafenib.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and reduced encorafenib and dabrafenib concentrations and efficacy when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: Dabrafenib may enhance the QTc-prolonging effect of Entrectinib. Dabrafenib may decrease the serum concentration of Entrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Enzalutamide. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Enzalutamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erdafitinib.  Management: Dose modifications of erdafitinib may be required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Exemestane. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fedratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of Dabrafenib. Dabrafenib may decrease the serum concentration of Fexinidazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: May enhance the QTc-prolonging effect of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fruquintinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fruquintinib.  Management: Avoid this combination when possible. If combined, continue the same fruquintinib dose, but monitor for reduced fruquintinib efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ganaxolone.  Management: Avoid concomitant use of ganaxolone and moderate CYP3A4 inducers whenever possible. If combined, consider increasing the dose of ganaxolone, but do not exceed the maximum recommended daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemigliptin: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gemigliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gepirone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glasdegib.  Management: Avoid use of glasdegib and moderate CYP3A4 inducers whenever possible. If combined, increase glasdegib dose from 100 mg daily to 200 mg daily or from 50 mg daily to 100 mg daily. Resume previous glasdegib dose 7 days after discontinuation of the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May enhance the QTc-prolonging effect of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a moderate CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrexafungerp. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Indinavir.  Management: Consider avoiding the combination of indinavir and moderate CYP3A4 inducers whenever possible due to the risk for decreased indinavir concentrations, reduced efficacy, and development of resistance. If combined, monitor for indinavir treatment failure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Moderate) may decrease isavuconazole serum concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Istradefylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixazomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Larotrectinib.  Management: Double the larotrectinib dose if used together with a moderate CYP3A4 inducer. Following discontinuation of the moderate CYP3A4 inducer, resume the previous dose of larotrectinib after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin (intravenous) with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Dabrafenib may enhance the QTc-prolonging effect of Levoketoconazole. Levoketoconazole may increase the serum concentration of Dabrafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of LinaGLIPtin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inducers (Moderate) may enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lorlatinib.  Management: Avoid use of lorlatinib with moderate CYP3A4 inducers. If such a combination must be used, increase lorlatinib to 125 mg daily. Monitor for reduced lorlatinib efficacy and consider closer monitoring of AST, ALT, and bilirubin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lumacaftor and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lumateperone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lurasidone.  Management: Monitor for decreased lurasidone effects if combined with moderate CYP3A4 inducers and consider increasing the lurasidone dose if coadministered with a moderate CYP3A4 inducer for 7 or more days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice/day, but only if not receiving a strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Contraindicated in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maribavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mefloquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Meperidine. Specifically, concentrations of normeperidine, the CNS stimulating metabolite, may be increased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Dabrafenib may enhance the QTc-prolonging effect of Methadone. Dabrafenib may decrease the serum concentration of Methadone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and reduced methadone efficacy. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mianserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: May enhance the QTc-prolonging effect of Dabrafenib. Dabrafenib may decrease the serum concentration of Midostaurin. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Also monitor for decreased midostaurin efficacy.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MiFEPRIStone.  Management: Avoid combined use in patients treated for Cushing's disease. When used for pregnancy termination, mifepristone efficacy may be reduced and an alternative pregnancy termination procedure may be warranted. Ensure a follow-up assessment after combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mitapivat.  Management: Consider alternatives to this combination when possible. If combined, monitor hemoglobin and titrate mitapivat beyond 50 mg twice daily, if needed, but do not exceed doses of 100 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: Dabrafenib may enhance the QTc-prolonging effect of Mobocertinib. Dabrafenib may decrease serum concentrations of the active metabolite(s) of Mobocertinib. Dabrafenib may decrease the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Netupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nevirapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Dabrafenib may enhance the QTc-prolonging effect of Nilotinib. Nilotinib may increase serum concentrations of the active metabolite(s) of Dabrafenib. Nilotinib may increase the serum concentration of Dabrafenib. Dabrafenib may decrease the serum concentration of Nilotinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Also monitor for decreased nilotinib efficacy and increased dabrafenib adverse effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olutasidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Omaveloxolone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: May enhance the QTc-prolonging effect of Dabrafenib. Dabrafenib may decrease the serum concentration of Osimertinib. Management: Monitor for decreased osimertinib efficacy, QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of OxyCODONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Dabrafenib may enhance the QTc-prolonging effect of PAZOPanib. Dabrafenib may decrease the serum concentration of PAZOPanib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Also monitor for reduced pazopanib efficacy.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pemigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Perampanel.  Management: Increase perampanel starting dose to 4 mg/day if used with moderate CYP3A4 inducers. Increase perampanel dose by 2 mg/day no more than once weekly based on response and tolerability. Dose adjustments may be needed if the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: May enhance the QTc-prolonging effect of Dabrafenib. Dabrafenib may decrease the serum concentration of Piperaquine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Also monitor for decreased piperaquine efficacy.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pirtobrutinib.  Management: Avoid concomitant use if possible. If combined, if the current pirtobrutinib dose is 200 mg once daily, increase to 300 mg once daily. If current pirtobrutinib dose is 50 mg or 100 mg once daily, increase the dose by 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, increase pralsetinib dose from 400 mg daily to 600 mg daily; from 300 mg daily to 500 mg daily; and from 200 mg daily to 300 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Praziquantel.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for reduced praziquantel efficacy. If possible, stop the moderate CYP3A4 inducer 2 to 4 weeks before praziquantel initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): Dabrafenib may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): Dabrafenib may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): Dabrafenib may enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Dabrafenib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Dabrafenib. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and dabrafenib adverse effects when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): Dabrafenib may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk). QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Dabrafenib.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Dabrafenib. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Dabrafenib. Management: Consider alternatives to these QT-prolonging strong CYP3A4 inhibitors for patients being treated with dabrafenib. If such a combination cannot be avoided, monitor closely for dabrafenib-related adverse effects, including QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Dabrafenib may enhance the QTc-prolonging effect of QUEtiapine. Dabrafenib may decrease the serum concentration of QUEtiapine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Also monitor for reduced quetiapine efficacy.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: Dabrafenib may enhance the QTc-prolonging effect of QuiNIDine. Dabrafenib may decrease the serum concentration of QuiNIDine.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and reduced quinidine efficacy. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: Dabrafenib may enhance the QTc-prolonging effect of QuiNINE. Dabrafenib may decrease the serum concentration of QuiNINE.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and reduced quinine efficacy. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: May enhance the QTc-prolonging effect of Dabrafenib. Dabrafenib may decrease the serum concentration of Quizartinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: Dabrafenib may enhance the QTc-prolonging effect of Ribociclib. Ribociclib may increase serum concentrations of the active metabolite(s) of Dabrafenib. Ribociclib may increase the serum concentration of Dabrafenib. Dabrafenib may decrease the serum concentration of Ribociclib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Also monitor for decreased ribociclib efficacy and increased dabrafenib adverse effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rilpivirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ripretinib.  Management: Avoid this combination if possible. If concomitant use is required, increase ripretinib to 150 mg twice daily. Decrease ripretinib to 150 mg once daily 14 days after stopping a moderate CYP3A4 inducer. Monitor patients for ripretinib response and toxicity<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Dabrafenib may enhance the QTc-prolonging effect of RisperiDONE. Dabrafenib may decrease the serum concentration of RisperiDONE.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Also monitor for reduced risperidone efficacy.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ritlecitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast (Systemic): CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Moderate) may decrease the serum concentration of Roflumilast (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rolapitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Samidorphan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Dabrafenib may enhance the QTc-prolonging effect of Selpercatinib. Dabrafenib may decrease the serum concentration of Selpercatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selumetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sertraline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SORAfenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sotorasib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: Dabrafenib may enhance the QTc-prolonging effect of SUNItinib. Dabrafenib may decrease the serum concentration of SUNItinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Also monitor for reduced sunitinib efficacy.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Suvorexant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tamoxifen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, sirolimus concentrations may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Temsirolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tivozanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tivozanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tofacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tolvaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: May enhance the QTc-prolonging effect of Dabrafenib. Dabrafenib may decrease the serum concentration of Toremifene. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Also monitor for reduced toremifene efficacy.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trametinib: May enhance the adverse/toxic effect of Dabrafenib. Trametinib may increase the serum concentration of Dabrafenib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Upadacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: Dabrafenib may enhance the QTc-prolonging effect of Vandetanib. Dabrafenib may increase serum concentrations of the active metabolite(s) of Vandetanib. Dabrafenib may decrease the serum concentration of Vandetanib.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and changes in vandetanib efficacy or toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: Dabrafenib may enhance the QTc-prolonging effect of Vemurafenib. Dabrafenib may decrease the serum concentration of Vemurafenib.  Management: Monitor for decreased vemurafenib efficacy, QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): CYP2C9 Inducers (Weak) may decrease the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vonoprazan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vortioxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxelotor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and moderate CYP3A4 inducers. If unavoidable, increase the voxelotor dose to 2,000 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zaleplon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zanubrutinib.  Management: Avoid this combination if possible. If coadministration of zanubrutinib and a moderate CYP3A4 inducer is required, increase the zanubrutinib dose to 320 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zuranolone. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F20608789"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Administration of capsules with a high-fat meal (~1,000 calories; 58 to 75 grams of fat, 58 g of carbohydrates, 33 g of protein) decreased C<sub>max </sub>and AUC by 51% and 31%, respectively, and delayed median T<sub>max </sub>by 3.6 hours (compared to a fasted state). Management: Administer 1 hour before or 2 hours after a meal.</p></div>
<div class="block rep_considerations drugH1Div" id="F49297369"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to treatment initiation in patients who could become pregnant. Dabrafenib may cause hormonal contraceptives to be ineffective. Patients who could become pregnant should use a highly effective nonhormonal contraceptive during dabrafenib therapy and for 2 weeks after the last dabrafenib dose. Males (including those with vasectomies) with pregnant partners or partners who could become pregnant should use condoms during dabrafenib treatment and for 2 weeks after the last dabrafenib dose.</p></div>
<div class="block pri drugH1Div" id="F20608784"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on its mechanism of action and on findings in animal reproduction studies, in utero exposure to dabrafenib may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F20608786"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if dabrafenib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during dabrafenib treatment and for 2 weeks after the last dabrafenib dose.</p></div>
<div class="block mop drugH1Div" id="F20608813"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">BRAF V600K or V600E mutation status (prior to treatment); serum glucose at baseline and as clinically necessary (particularly in patients with preexisting diabetes mellitus or hyperglycemia); electrolytes; renal function. Verify pregnancy status prior to treatment initiation (in patients who could become pregnant). Perform dermatologic evaluations prior to initiation, every 2 months during therapy, and for up to 6 months following discontinuation to assess for new cutaneous malignancies. Monitor for febrile drug reactions and signs/symptoms of infections; monitor serum creatinine and other evidence of renal function during and after serious fever. Monitor for signs/symptoms of uveitis (eg, eye pain, photophobia, vision changes). Monitor for signs/symptoms of hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency, new or worsening dermatologic toxicity (including severe cutaneous adverse reactions), and for noncutaneous malignancies.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">For patients receiving combination therapy with trametinib: Hepatic function; CBC (baseline and periodically during therapy); assess left ventricular ejection fraction (by echocardiogram or multigated acquisition scan [MUGA] scan) at baseline, 1 month after therapy initiation, and then at 2- to 3-month intervals while on treatment. Monitor for signs/symptoms of hemorrhage, venous thromboembolism, interstitial lung disease, and hemophagocytic lymphohistiocytosis. Monitor for signs/symptoms of retinal pigment epithelial detachment or retinal vein occlusion; promptly (within 24 hours) refer patients for ophthalmological evaluations if loss of vision or other visual disturbances occur; ophthalmic exams (including retinal evaluation) should be performed periodically during treatment with combination therapy.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Cardiovascular monitoring specifics: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]). Assess BP at baseline and each clinical visit (as well as outpatient monitoring weekly for initial 3 months, then monthly thereafter), obtain a baseline echocardiography in high- and very-high risk patients scheduled to receive BRAF-MEK inhibitor combination therapy (consider repeating every 4 months during the first year); consider echocardiography in low- and moderate-risk patients scheduled to receive BRAF-MEK inhibitor combination therapy (ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F20608792"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dabrafenib selectively inhibits some mutated forms of the protein kinase B-raf (BRAF). BRAF V600 mutations result in constitutive activation of the BRAF pathway; through BRAF inhibition, dabrafenib inhibits tumor cell growth. The combination of dabrafenib and trametinib allows for greater inhibition of the MAPK pathway, resulting in BRAF V600 melanoma cell death (Flaherty 2012). Dabrafenib plus trametinib has been reported to synergistically inhibit cell growth in lung cancer cell lines which are BRAF V600E-mutant (Planchard 2016). Induction of EGFR-mediated MAPK pathway reactivation in the setting of BRAF-mutant colorectal cancer has been identified as a mechanism of intrinsic resistance to BRAF inhibitors.</p></div>
<div class="block phk drugH1Div" id="F20608794"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Decreased when capsules are administered with a high-fat meal (~1,000 calories; 58 to 75 grams of fat).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 70.3 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99.7% to plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP2C8 and CYP3A4 to hydroxy-dabrafenib (active) which is further metabolized via CYP3A4 oxidation to desmethyl-dabrafenib (active).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Capsules: 95%; Tablets for oral suspension: 76%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Parent drug: 8 hours; Hydroxy-dabrafenib (active metabolite): 10 hours; Desmethyl-dabrafenib (active metabolite): 21 to 22 hours; Carboxy-dabrafenib (21 to 22 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 hours; delayed with a high-fat meal (~1,000 calories; 58 to 75 grams of fat).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (71%); urine (23%; metabolites only).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 17 L/hour (single dose); 34.4 L/hour (after 2 weeks of twice-daily dosing).</p></div>
<div class="block phksp drugH1Div" id="F51435810"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Hepatic function impairment:</b> Patients with moderate (bilirubin &gt;1.5 to 3 times ULN and any AST) or severe (bilirubin &gt;3 to 10 times ULN and any AST) hepatic impairment may have increased dabrafenib exposure.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23777406"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Rafinlar</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Rafinlar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Rafinlar | Tafinlar</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Tafinlar</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36375115">
<a name="36375115"></a>Bouffet E, Geoerger B, Moertel C, et al. Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric <i>BRAF</i> V600-mutant low-grade glioma. <i>J Clin Oncol</i>. 2023;41(3):664-674. doi:10.1200/JCO.22.01000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/36375115/pubmed" id="36375115" target="_blank">36375115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32877599">
<a name="32877599"></a>Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. <i>N Engl J Med</i>. 2020;383(12):1139-1148. doi:10.1056/NEJMoa2005493<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/32877599/pubmed" id="32877599" target="_blank">32877599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23020132">
<a name="23020132"></a>Flaherty KT, Infante JR, Daud A, et al, “Combined BRAF and MEK Inhibition in Melanoma With BRAF V600 Mutations,” <i>N Engl J Med</i>, 2012, 367(18):1694-703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/23020132/pubmed" id="23020132" target="_blank">23020132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31811016">
<a name="31811016"></a>Hargrave DR, Bouffet E, Tabori U, et al. Efficacy and safety of dabrafenib in pediatric patients with <i>BRAF</i> V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I/IIa study. <i>Clin Cancer Res</i>. 2019;25(24):7303-7311. doi:10.1158/1078-0432.CCR-19-2177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/31811016/pubmed" id="31811016" target="_blank">31811016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22735384">
<a name="22735384"></a>Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAf-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial. <i>Lancet</i>. 2012;380(9839):358-365. doi:10.1016/S0140-6736(12)60868-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/22735384/pubmed" id="22735384" target="_blank">22735384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31506385">
<a name="31506385"></a>Kieran MW, Geoerger B, Dunkel IJ, et al. A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory <i>BRAF</i> V600 mutation-positive solid tumors. <i>Clin Cancer Res</i>. 2019;25(24):7294-7302. doi:10.1158/1078-0432.CCR-17-3572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/31506385/pubmed" id="31506385" target="_blank">31506385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28891408">
<a name="28891408"></a>Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. <i>N Engl J Med</i>. 2017;377(19):1813-1823. doi:10.1056/NEJMoa1708539.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/28891408/pubmed" id="28891408" target="_blank">28891408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26037941">
<a name="26037941"></a>Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i>. 2015;386(9992):444-451. doi:10.1016/S0140-6736(15)60898-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/26037941/pubmed" id="26037941" target="_blank">26037941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23051966">
<a name="23051966"></a>Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicenter, open-label, phase 2 trial. <i>Lancet Oncol</i>. 2012;13(11):1087-1095. doi:10.1016/S1470-2045(12)70431-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/23051966/pubmed" id="23051966" target="_blank">23051966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mekinist.1">
<a name="Mekinist.1"></a>Mekinist (trametinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26922422">
<a name="26922422"></a>Parakh S, Goh M, Andrews MC. Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib. <i>J Clin Pharm Ther</i>. 2016;41(3):354-356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/26922422/pubmed" id="26922422" target="_blank">26922422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27283860">
<a name="27283860"></a>Planchard D, Besse B, Groen HJ, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncol</i>. 2016;17(7):984-993.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/27283860/pubmed" id="27283860" target="_blank">27283860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34455067">
<a name="34455067"></a>Planchard D, Besse B, Groen HJM, et al. Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. <i>J Thorac Oncol</i>. 2022;17(1):103-115. doi:10.1016/j.jtho.2021.08.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/34455067/pubmed" id="34455067" target="_blank">34455067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25399551">
<a name="25399551"></a>Robert C, Karaszewska B, Schachter J, et al. Schadendorf D. Improved overall survival in melanoma with combined dabrafenib and trametinib. <i>N Engl J Med</i>. 2015;372(1):30-39. doi:10.1056/NEJMoa1412690<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/25399551/pubmed" id="25399551" target="_blank">25399551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32758030">
<a name="32758030"></a>Salama AKS, Li S, Macrae ER, et al. Dabrafenib and trametinib in patients with tumors with <i>BRAFV600E</i> mutations: results of the NCI-MATCH trial subprotocol H. <i>J Clin Oncol</i>. 2020;38(33):3895-3904. doi:10.1200/JCO.20.00762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/32758030/pubmed" id="32758030" target="_blank">32758030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35026411">
<a name="35026411"></a>Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. <i>Ann Oncol</i>. 2022;33(4):406-415. doi:10.1016/j.annonc.2021.12.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/35026411/pubmed" id="35026411" target="_blank">35026411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29072975">
<a name="29072975"></a>Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. <i>J Clin Oncol.</i> 2018;36(1):7-13. doi:10.1200/JCO.2017.73.6785.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/29072975/pubmed" id="29072975" target="_blank">29072975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32818466">
<a name="32818466"></a>Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncol</i>. 2020;21(9):1234-1243. doi:10.1016/S1470-2045(20)30321-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/32818466/pubmed" id="32818466" target="_blank">32818466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tafinlar.1">
<a name="Tafinlar.1"></a>Tafinlar (dabrafenib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tafinlar.2">
<a name="Tafinlar.2"></a>Tafinlar (dabrafenib) [product monograph]. Montreal, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed October 4, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34838156">
<a name="34838156"></a>Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. <i>Lancet Oncol</i>. 2022;23(1):53-64. doi:10.1016/S1470-2045(21)00578-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/34838156/pubmed" id="34838156" target="_blank">34838156</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 89686 Version 313.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
